Immune checkpoint inhibitors have revolutionized the treatment paradigm of several cancers. However, not all patients respond to treatment. Tumor cells reprogram metabolic pathways to facilitate growth and proliferation. This shift in metabolic pathways creates fierce competition with immune cells for nutrients in the tumor microenvironment and generates by-products harmful for immune cell differentiation and growth. In this review, we discuss these metabolic alterations and the current therapeutic strategies to mitigate these alterations to metabolic pathways that can be used in combination with checkpoint blockade to offer a new path forward in cancer management.

immune checkpoint inhibitors, glucose metabolism, amino acid metabolism, lipid metabolism, adenosine pathway
This content is only available as a PDF.

Competing Interests

Source of Support: None. Conflict of Interest: None.

2023
This work is published under a CC-BY-NC-ND 4.0 International License.